Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors
- Determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with
unresectable or metastatic urothelial cancer (nontransitional cell histologies).
OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1
and ifosfamide IV over 1 hour on days 1-3. Filgrastim (G-CSF) is administered subcutaneously
daily beginning on day 6 and continuing through day 17 or until blood counts recover.
Treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or
progressive disease after completion of course 2 or complete response after completion of
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|